dexrazoxane / Generic mfg. - LARVOL DELTA

Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research. (PubMed, Medicines (Basel)) - "For the past three decades, dexrazoxane has been the sole Food and Drug Administration-approved agent for cardioprotection in this setting. However, in the current era of novel therapies with multi-system benefits-such as GLP-1 RAs-we propose a theoretical framework exploring their potential role in mitigating AIC and underscore the need for further clinical investigation in this new arena in the field of cardio-oncology."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • Oncology • Type 2 Diabetes Mellitus

COMPARATIVE EFFICACY AND SAFETY OF CARDIOPROTECTIVE DRUGS IN PREVENTING CHEMOTHERAPY-INDUCED CARDIOTOXICITY IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (ACC 2026) - "Treatment groups were dexrazoxane (n=1,211), carvedilol (n=91), enalapril (n=163), atorvastatin (n=25), and placebo (n=1,447); in total, 1,490 patients received active cardioprotection. Dexrazoxane ranked highest in SUCRA analysis, significantly preserving LVEF. Overall, cardioprotective drugs were safe but showed limited impact on biomarkers or clinical outcomes in pediatric and AYA patients."

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Pediatrics

COMPARATIVE EFFECTIVENESS OF CONTINUOUS INFUSION, DEXRAZOXANE, EPIRUBICIN, AND LIPOSOMAL DOXORUBICIN FOR PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY: A NETWORK META-ANALYSIS (ACC 2026) - "Preventive strategies include continuous infusion (CIV), dexrazoxane, epirubicin, and pegylated liposomal doxorubicin (PLD), but they have been tested only in isolation. PLD, dexrazoxane, and CIV each reduced anthracycline cardiotoxicity by ~75-80% versus bolus doxorubicin, while epirubicin provided moderate benefit, with efficacy preserved across all strategies. This unified comparative ranking offers a robust evidence base for cardio-oncology guidelines and survivorship care."

HEOR • Retrospective data • Breast Cancer • Cardiovascular • Hematological Malignancies • Mucositis • Sarcoma • Solid Tumor

DEXRAZOXANE SIGNIFICANTLY REDUCES ANTHRACYCLINE-INDUCED CARDIAC DYSFUNCTION IN ADULT PATIENTS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - "Dexrazoxane has a cardioprotective effect; however, it can lead to hematological adverse events. More trials are needed, especially in non-breast cancer."

Retrospective data • Review • Breast Cancer • Congestive Heart Failure • Heart Failure • Neutropenia • Sarcoma • Solid Tumor • Thrombocytopenia

Chemotherapy-Induced Cardiotoxicity: A Comprehensive Review of Current Understanding and Future Directions. (PubMed, Curr Cardiol Rev) - "Chemotherapy-induced cardiotoxicity continues to challenge clinicians striving for a cure without compromise. The future of cancer care lies in integrating precision medicine with preventive cardiology to minimize cardiac injury while maintaining therapeutic efficacy. Continued research into molecular targets, biomarkers, and cell-based therapies offers genuine hope for improving both survival and quality of life in cancer patients."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Ischemia • Obesity • Oncology • Transplantation

Effects of anthracyclines on arteriosclerosis and the protective effect of dexrazoxane in breast cancer patients. (PubMed, J Chemother) - "The PWV value was significantly increased in the control group (p < 0.001). In patients who have received anthracyclines, dexrazoxane was protective against arteriosclerosis as demonstrated by statistically significant changes in aortic stiffness and PWV values."

Journal • Atherosclerosis • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

DFCI 21-757: Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Andrew E. Place, MD | Active, not recruiting ➔ Recruiting | N=13 ➔ 30 | Trial completion date: Jul 2028 ➔ Jul 2030 | Trial primary completion date: Jul 2026 ➔ Jul 2028

Enrollment change • Enrollment open • Pan tumor • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Oncology • ABL1 • BCL2 • BCR • FLT3 • IKZF1 • KMT2A

Heart transplantation in pediatric oncology patients. (PubMed, JHLT Open) - "CTRCD is often irreversible and progressive; it is imperative that such damage be prevented with strategies such as limiting cumulative anthracycline exposures, utilizing anthracycline-sparing regimens when feasible, and increasing the use of cardioprotective agents like dexrazoxane...Heart transplantation is a viable and effective treatment for select CCS with end-stage heart failure. Careful multidisciplinary evaluation, tailored immunosuppression, and vigilant long-term surveillance are essential to optimize outcomes in this complex population."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Infectious Disease • Oncology • Pediatrics • Transplantation

APPROVED AND EMERGING OPTIONS FOR ONCOLOGY TREATMENT-RELATED TOXICITIES: A TARGETED LITERATURE REVIEW OF THE LANDSCAPE AND REMAINING UNMET NEEDS (ISPOR 2026) - "Agents were cataloged by intended use: (a) rescue therapies for acute overdose or early severe toxicity (e.g., glucarpidase, uridine triacetate, leucovorin rescue); (b) prophylactic organ-protective agents (e.g., mesna, amifostine, dexrazoxane, sodium thiosulfate, palifermin, trilaciclib); (c) countermeasures for immune-mediated toxicities (e.g., tocilizumab for cytokine release syndrome); and (d) radiation normal-tissue protectants in development (e.g., superoxide dismutase mimetics, avasopasem [GC-4419]). Across drug classes, agents demonstrated substantial clinical benefit in narrow, time-sensitive indications (e.g., rescue for high-dose methotrexate or fluoropyrimidine toxicity; cardioprotection with dexrazoxane; otoprotection with sodium thiosulfate in pediatric cisplatin-treated patients; and reduced mucositis with palifermin in select HSCT regimens)... Timely rescue administration can improve outcomes for patients experiencing severe treatment-related toxicities...."

Review • Bone Marrow Transplantation • Cardiovascular • Inflammation • Mucositis

Anthracyclines and the Heart: A Double-edged Sword With Therapeutic Hopes. (PubMed, J Saudi Heart Assoc) - "Anthracyclines, notably doxorubicin, are potent cytotoxic agents that substantially improved outcomes across numerous malignancies...Neurohormonal modulation with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-blockers has shown modest preservation of left ventricular ejection fraction, especially when initiated early in high-risk patients; spironolactone appears more effective than eplerenone among mineralocorticoid receptor antagonists. Sacubitril/valsartan demonstrates promising superiority in preclinical and early clinical cohorts, though further randomised control trials are ongoing. Metabolic modulators such as metformin and sodium-glucose cotransporter 2 inhibitors exhibit cardio-protectivity via AMPK activation, attenuation of oxidative and inflammatory pathways, but evidence in non-diabetic cancer populations is limited. Statins have shown reduced left ventricular ejection fraction decline and lower cardiotoxicity rates in..."

Journal • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Oncology • Pediatrics

Network pharmacology-based therapeutic intervention of Mentha arvensis targeting cancer and doxorubicin-induced cardiotoxicity. (PubMed, Invest New Drugs) - "Phytochemicals derived from Mentha arvensis demonstrate potential as dual-action agents capable of mitigating doxorubicininduced cardiotoxicity while preserving anticancer activity. However, when used alone, these compounds exhibited only moderate therapeutic potential. Combinatorial strategies involving Dexa may enhance cardioprotective efficacy while reducing associated limitations, possibly through modulation of ferroptosis-related pathways. Nevertheless, rigorous experimental validation remains essential. Future studies should employ well-established in vivo oncogenic cardiotoxicity models incorporating Dox, Dexa, and phytochemicals concurrently to elucidate shared molecular targets and confirm therapeutic efficacy against both cancer and DIC."

Journal • Addiction (Opioid and Alcohol) • Bladder Cancer • Cardiovascular • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Kaposi Sarcoma • Leukemia • Lymphoma • Oncology • Pediatrics • Sarcoma • Solid Tumor • AKR1B1 • CDK2 • HMOX1 • MMP2 • PACERR • PTGS2 • SIRT1 • TNFA

Metastasis of small cell Lung Carcinoma to a Lipofibrom. A rare clinical case report. (DKK 2026) - "Due to the long history and progression, a repeat biopsy revealed a fibroadenoma.This met the criteria for tumor-to-tumor metastasis, with SCLC metastasizing into a pre-existing fibroadenoma.The patient underwent six cycles of palliative chemotherapy with carboplatin and etoposide; due to progression, treatment was continued with oral topotectan. This case highlights the importance of critically evaluating and histologically confirming seemingly benign lesions in oncologic patients with aggressive tumors, particularly when there is clinical suspicion of atypical behavior. Indication of source 1. Georgiou LA et al."

Case report • Clinical • Brain Cancer • Breast Cancer • Lung Cancer • Meningioma • Oncology • Small Cell Lung Cancer • Solid Tumor • Thyroid Gland Carcinoma • SYP

Advances in Analytical Strategies for Precise Quantification of Topoisomerase Inhibitors: Current Trends and Future Directions. (PubMed, Biomed Chromatogr) - "This review critically evaluates current analytical approaches for determining widely used TIs, including topotecan, irinotecan, etoposide, epirubicin, dexrazoxane, and camptothecin, with emphasis on selectivity, sensitivity, applicability, and robustness in complex matrices. In contrast, ultrahigh-performance liquid chromatography coupled with tandem or high-resolution mass spectrometry (UHPLC-MS/MS or UHPLC-HRMS) provides superior selectivity, sub-ng mL-1 sensitivity, and reliable discrimination of parent drugs and metabolites across diverse matrices. Overall, UHPLC-MS-based methods emerge as the current gold standard for TI quantification, supporting clinical, pharmacokinetic, and regulatory applications in modern analytical science."

Journal • Review • Oncology

Guizhi Gancao Decoction Protects Against Doxorubicin-induced Cardiotoxicity by Intervening in Microtubule Acetylation. (PubMed, J Ethnopharmacol) - "Our findings suggest that GGD protects against DIC, potentially through inhibition of HDAC6-mediated α-tubulin deacetylation, which stabilizes microtubules, ensures T-tubule integrity and calcium-handling protein distribution, and ultimately preserves cardiomyocyte Ca2+ handling and contractile function. We acknowledge several limitations: the findings are derived from a single batch, the definitive causal role of HDAC6 requires validation in genetic models, and the specific bioactive components responsible for the observed effects remain to be identified. Validation across multiple batches and further mechanistic studies are warranted to confirm and extend these findings."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • HDAC6 • RYR2

Countermeasures for anthracycline-induced cardiomyopathy Triple-negative breast cancer, positioning of dexrazoxane (JSMO 2026) - No abstract available

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Molecular Insights into Doxorubicin-Induced Cardiotoxicity and Phytochemical-Based Cardioprotection: Challenges and Future Strategies. (PubMed, Drug Metab Rev) - "Although dexrazoxane is the only FDA-approved cardioprotective agent, concerns about its long-term safety and potential interference with doxorubicin's antitumor effectiveness have increased the search for safer alternatives. Despite promising preclinical evidence of their antioxidant, anti-inflammatory, and anti-apoptotic properties, the clinical use of phytochemicals is limited by issues such as low bioavailability, poor specificity, dose-dependent toxicity, variable pharmacokinetics, and lack of standardisation. Therefore, innovative approaches-such as ligand-targeted delivery systems, nanotechnology-based formulations, and structural modifications of lead compounds-are essential to enhance their pharmacological properties, safety, and therapeutic effectiveness for effective cardioprotection against doxorubicin-induced toxicity."

Journal • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Oncology • AMPK • KEAP1 • SIRT1

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826 (ASH 2023) - P3 | "Dexrazoxane was permitted, but not mandated. In early follow-up, N-AVD and BV-AVD are well tolerated and associated with low rates of irAEs in pts ages 12-17 y. With 12.1 mos median follow-up the PFS benefit observed for N-AVD in pediatric pts mirrors that observed in the overall study. RT usage is lower, and cumulative doxorubicin dose is higher than historical pediatric cHL trials. The difference in rate of discontinuation between study arms and by age group needs further evaluation."

Clinical • Metastases • Classical Hodgkin Lymphoma • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Inflammation • Lymphoma • Neutropenia • Oncology • Pediatrics • Pneumonia • Septic Shock

PROGRESSION-FREE SURVIVAL (PFS) WITH NIVOLUMAB-AVD IS SUPERIOR TO BRENTUXIMAB VEDOTIN-AVD WITH 2-YEAR FOLLOW-UP OF S1826 IN ADOLESCENT ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (CHL) (ISHL 2024) - P3 | "80% of adolescent pts received dexrazoxane. N-AVD is well tolerated in adolescents 12–17 y, with high PFS and EFS and minimal use of RT compared to prior pediatric HL studies. N-AVD is a new standard of care for adolescents with AS cHL."

Metastases • Endocrine Disorders • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pain • Pediatrics • Septic Shock

AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - P2 | N=206 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Dexrazoxane Protects Against Hand-Foot Syndrome-Like Skin Damage in Pegylated Liposomal Doxorubicin-Treated Mice. (PubMed, J Toxicol) - "Although not significant, Topo IIα expression followed an analogous pattern to Topo IIβ expression. In conclusion, we demonstrated that DXZ inhibited PLD-induced skin damage."

Journal • Preclinical • Cardiovascular • Dermatology • Oncology

Mechanisms of Bellidifolin in Treating Doxorubicin-Induced Cardiotoxicity: Network Pharmacology, Molecular Docking, and Experimental Verification. (PubMed, Front Biosci (Landmark Ed)) - "BEL presents as a promising therapeutic candidate for cardiotoxicity, likely through its anti-fibrotic effects via the reduction of TGF-β1, α-SMA, Col I, and Col III expression, alongside regulation in the PI3K-AKT signaling pathway."

Journal • Cardiovascular • Fibrosis • Immunology • TGFB1

Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology. (PubMed, Discoveries (Craiova)) - "HER2-directed therapies, such as trastuzumab, interfere with cardioprotective ErbB signaling, typically producing reversible cardiac impairment. Preventive and management strategies incorporate cardioprotective agents like ACE inhibitors, β-blockers, dexrazoxane, and emerging therapies such as SGLT2 inhibitors. Modern cardio-oncology emphasizes a multidisciplinary, precision-based approach integrating early detection, genetic risk assessment, and targeted prophylaxis to preserve cardiac function while maintaining oncologic efficacy, thereby enhancing both survival and quality of life for cancer patients."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Metabolic Disorders • Oncology • ICOS

ICG-001 Provides Cardioprotection Against Doxorubicin-Induced Cardiotoxicity and Enhances Cancer Cytotoxicity. (PubMed, JACC Basic Transl Sci) - "This study demonstrates that ICG-001 suppressed DCT in patient-derived human induced pluripotent stem cell-derived cardiomyocytes in vitro and in mice in vivo, comparable to conventional treatment, dexrazoxane. Mechanistically, ICG-001 protected the mitochondria in cardiomyocytes via DPR1 inhibition, but suppressed cancer by repressing Wnt signaling. These dual mechanisms underscore the potential of ICG-001 as an adjunct treatment to doxorubicin to improve its safety and efficacy."

Journal • Cardiovascular • Oncology

Condensin II mediates resistance to genotoxic stress and prevents mitotic defects in Arabidopsis. (PubMed, Plant Physiol) - "The anaphase bridges were more frequent upon treatment with zebularine or ICRF-187 and the duration of mitosis was prolonged. Altogether, we demonstrate that proper large-scale chromatin organization by Condensin II is important for resistance to DNA damage in Arabidopsis."

Journal

AEWS1031: Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma (clinicaltrials.gov) - P3 | N=642 | Completed | Sponsor: Children's Oncology Group | Unknown status ➔ Completed

Trial completion • Trial completion date • Embryonal Tumor • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor